drugset
drugset / Trial / NCT03229252

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

NCT03229252 ↗

Phase 2 Completed 91 enrolled Spyryx Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Timeline

Start
2017-08-01
Primary completion
2019-06-20
Completion
2019-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject SPX-101 Protein / enzyme biologic — Inhaled

Indications

cystic fibrosis